MedUnfold

venetoclax

VenclextaBCL-2 inhibitor

Venclexta (venetoclax) is a BCL-2 inhibitor from AbbVie used in chronic lymphocytic leukemia and small lymphocytic lymphoma, alone or with other antibodies depending on line of therapy, and with a hypomethylating agent in newly diagnosed acute myeloid leukemia when intensive chemotherapy is not suitable.

This page is based on the official US label for VENCLEXTA and the EMA medicine record for Venclyxto, cross-checked with MedlinePlus and the NCI Drug Dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.

How it works

Explains what the medicine does in the body, not dosing, side effects, or safety.

An analogy

Cancer cells often keep themselves alive by holding on to a survival protein called BCL-2, like a hand gripping a ledge. Venetoclax pries that hand open, so the cancer cell lets go and triggers its own built-in self-destruct program.

In simple terms

Venetoclax is a tablet that blocks BCL-2, a protein leukemia cells use to avoid dying. When BCL-2 is blocked, the cancer cells can no longer survive and are cleared away. It is used in certain leukemias and lymphomas, often together with other medicines.

In depth

Venetoclax is an orally bioavailable, selective small-molecule inhibitor of the anti-apoptotic protein BCL-2. It mimics BH3-only proteins by binding the hydrophobic groove of BCL-2, displacing pro-apoptotic factors and restoring apoptosis in tumor cells that overexpress BCL-2. Because it spares BCL-XL, venetoclax causes less platelet toxicity than earlier BCL-2 family inhibitors. In CLL and AML it is used alone or combined with anti-CD20 antibodies, BTK inhibitors, or hypomethylating agents.

See it in motion

A schematic animation of the mechanism — simplified for clarity, not drawn to scale.

How venetoclax lets the cancer cell go

a survival protein called BCL-2venetoclaxrestoring apoptosis
  1. Some cancer cells overproduce BCL-2, a protein that blocks their own programmed cell death.
  2. Cancer cells often keep themselves alive by holding on to a survival protein called BCL-2, like a hand gripping a ledge. Venetoclax pries that hand open, so the cancer cell lets go and triggers its own built-in self-destruct program.
  3. When BCL-2 is blocked, the cancer cells can no longer survive and are cleared away.
  4. Tumor burden shrinks as those cells are cleared.
How venetoclax works

Target: B-cell lymphoma 2 (BCL-2) protein

An anti-apoptotic protein that many leukemia cells rely on to stay alive and resist treatment.

Approved uses

Approved uses differ by country and change over time. Always follow your local prescribing information.

Approved uses in United States

FDA
  • Treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
  • In combination with azacitidine, or decitabine, or low-dose cytarabine for newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy

Approved uses in European Union

EMA
  • Previously untreated chronic lymphocytic leukaemia (CLL) in adults, in combination with acalabrutinib with or without obinutuzumab, in combination with obinutuzumab, or in combination with ibrutinib
  • CLL in adults in combination with rituximab after at least one prior therapy
  • CLL as monotherapy in the presence of 17p deletion or TP53 mutation in adults who are unsuitable for or have failed a B cell receptor pathway inhibitor, or in the absence of 17p deletion or TP53 mutation in adults who have failed both chemoimmunotherapy and a B cell receptor pathway inhibitor
  • Newly diagnosed acute myeloid leukaemia (AML) in adults who are ineligible for intensive chemotherapy, in combination with a hypomethylating agent

Official sources

The statements on this page trace back to these records.

  1. Venclyxto (venetoclax) — Summary of product characteristics and package leaflet, English version

    European Medicines Agency

  2. openFDA drug label record for venetoclax (Venclexta)

    U.S. Food and Drug Administration, openFDA

  3. MedlinePlus: venetoclax

    MedlinePlus, U.S. National Library of Medicine

  4. NCI Drug Dictionary: venetoclax

    National Cancer Institute

This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.

MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.